Approach to Partnering

Oxagen’s strategy in the near term is to develop molecules from lead optimisation through “proof of concept” Phase IIa/IIb studies in man before identifying partners for further development and commercialisation and to broaden its pipeline through collaborations and licensing. We have, therefore three major areas of partnering interest.

Firstly, Oxagen intends to out-license its lead once a day oral molecule for asthma (CRTH2 antagonist) following demonstration of efficacy in man. The molecule is currently in Phase IIa clinical studies (see above) .

Secondly, We are focussed on advancing the pipeline of genetically validated GPCR targets for the development of therapies for inflammatory and autoimmune disease and are seeking drug discovery and development partnerships on these targets. These include – GPCRs for known drug targets with already marketed products where Oxagen’s genetic association highlights alternative indications, GPCRs for drug targets that are current and known drug development targets and orphan GPCRs. Opportunities exist within the Oxagen GPCR targets for indication switches of marketed drugs or drugs in earlier stages of development.

Thirdly, Oxagen welcomes approaches from partners with in-licensing opportunities on drug candidates which are complimentary to our in house expertise and existing pipeline. The primary focus for in licensing discussions is in the area of respiratory and inflammation at lead optimisation, preclinical, or Phase I development stages.